Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan flag Japan · Delayed Price · Currency is JPY
3,825.00
-15.00 (-0.39%)
Nov 13, 2026, 3:30 PM JST

Kaken Pharmaceutical Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
11,5722,31319,4359,7966,81713,885
Depreciation & Amortization
3,8983,3252,5542,7532,5682,486
Loss (Gain) From Sale of Assets
-392-3781,5551671,9112,896
Loss (Gain) From Sale of Investments
-1,152-2,014287-13-1-1
Other Operating Activities
-2,053-10,654-842-3,788-4,407-4,431
Change in Accounts Receivable
2,2221,8433,577-4,559972392
Change in Inventory
-3,027-59-1,084-1,603-583241
Change in Accounts Payable
1,728-7691,100880280-2,630
Change in Other Net Operating Assets
-1,619-4,6863,198-1,0561,696498
Operating Cash Flow
11,177-11,07929,7802,5779,25313,336
Operating Cash Flow Growth
--1055.61%-72.15%-30.62%-7.26%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-3,643-2,996-4,138-1,861-1,987-2,986
Sale of Property, Plant & Equipment
3,1413,141-112704
Cash Acquisitions
1616-15,378---4,975
Sale (Purchase) of Intangibles
-2,264-2,427-254-306-219-271
Investment in Securities
1,1222,915120516-1955
Other Investing Activities
-471-334--4,204-238-365
Investing Cash Flow
-2,099315-19,650-5,854-2,627-7,888

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Issuance of Common Stock
--7,764---
Repurchase of Common Stock
-2-2,343-5,935--1,340-2,414
Common Dividends Paid
-7,219-6,498-7,198-5,657-5,649-5,714
Other Financing Activities
----1-1-1
Financing Cash Flow
-7,221-8,841-5,369-5,658-6,990-8,129

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
554225----
Miscellaneous Cash Flow Adjustments
-1--1--1
Net Cash Flow
2,410-19,3804,760-8,935-364-2,680

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
7,534-14,07525,6427167,26610,350
Free Cash Flow Growth
--3481.28%-90.15%-29.80%-16.58%
Free Cash Flow Margin
8.71%-18.31%27.27%0.99%9.96%13.61%
Free Cash Flow Per Share
198.95-371.26671.9218.97193.39272.53
Levered Free Cash Flow
4,492-14,29322,980-1,2997,4868,025
Unlevered Free Cash Flow
4,527-14,26522,998-1,2897,4978,036

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
564528171717
Cash Income Tax Paid
2,04710,6548363,7884,4094,431
Change in Working Capital
-696-3,6716,791-6,3382,365-1,499